A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.
Key Details
- 1Researchers from Peking Union Medical College Hospital and Tsinghua University developed a compact optical AI chip for MGD diagnosis.
- 2The AI chip integrates a spectral convolutional neural network (SCNN) directly onto a CMOS imaging sensor.
- 3Pathological tissue sections from MGD patients and controls were rapidly analyzed, producing spectral feature maps in tens of milliseconds.
- 4The chip identifies MGD with 96.22% accuracy, outperforming conventional RGB image analysis (84%) and matching hyperspectral imaging.
- 5Distinct spectral signatures corresponded with disease severity and biochemical changes in gland tissue.
- 6The device is CMOS-fabricated, enabling potential clinical integration for real-time, objective ocular assessment.
Why It Matters
This innovation demonstrates the power of combining metasurface optics and AI for rapid, objective tissue diagnostics—reducing reliance on subjective clinical assessment and paving the way for real-time, in-sensor medical AI applications.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.